These results suggested that LOXL2 might be a useful biomarker in predicting patient prognosis, especially in LUAD, CESC, PAAD, and ACC, and the contribution of LOXL2 in tumor progression is yet to be fully elucidated. The gene discussed is LOXL2; the disease is adrenal cortex carcinoma.